[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100440807":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":21,"locations":27,"responsibleParty":44,"collaborators":48,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":10,"eligibilityCriteria":66,"healthyVolunteers":67,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":10,"studyType":74,"phases":10,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":30,"whyStopped":10,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Capital Medical University","OTHER",[8,12,15,18],{"label":9,"type":10,"description":11,"interventionNames":10},"Alzheimer's disease",null,"Criteria for AD according to the 2011 NIA-AA",{"label":13,"type":10,"description":14,"interventionNames":10},"MCI group","aMCI diagnosed according to the criteria of 2004 Peterson.",{"label":16,"type":10,"description":17,"interventionNames":10},"Non-AD dementia","Frontotemporal dementia (FTD); or Parkinson's disease dementia (PDD); or dementia with Lewy bodies (DLB); or vascular dementia (VaD); or corticobasal degeneration (CBD); or dementia not otherwise specified.",{"label":19,"type":10,"description":20,"interventionNames":10},"Cognitively normal controls","Individuals with normal cognitive function",[22],{"name":23,"role":24,"phone":25,"phoneExt":10,"email":26},"Jianping Jia, Doctor","CONTACT","8610-83199449","jiajp@vip.126.com",[28],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Xuanwu Hospital of Capital Medical University","RECRUITING","Beijing","Beijing Municipality","100053","China","CN",{"type":37,"coordinates":38},"Point",[39,40],116.39723,39.9075,{"lat":40,"lon":39},[43],{"name":23,"role":24,"phone":25,"phoneExt":10,"email":26},{"type":45,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Jianping Jia","Chief Director",[49,52,54,56,58],{"name":50,"class":51},"Shandong Provincial Hospital","OTHER_GOV",{"name":53,"class":6},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"name":55,"class":6},"Xiangya Hospital of Central South University",{"name":57,"class":6},"Huashan Hospital",{"name":59,"class":6},"The First Hospital of Jilin University","100440807","the-diagnostic-cut-off-value-of-core-biomarkers-of-alzheimers-disease-100440807",false,"NCT05020106","The Diagnostic Cut-off Value of Core Biomarkers of Alzheimer's Disease","Study on the Diagnostic Cut-off Value of Core Biomarkers in Cerebrospinal Fluid and Blood of Alzheimer's Disease","Inclusion Criteria:\n\n* Aged 55-75. Written informed consent obtained from participant or legal guardian prior to any study-related procedures. The diagnosis of AD is made using the National Institute on Aging and the Alzheimer's Association (NIA-AA) criteria. The diagnosis of aMCI is assigned according to 2004 Petersen criteria. As for non-AD dementia, the McKeith criteria are used for DLB, the revised diagnostic criteria proposed by the International bvFTD Criteria Consortium for behavioral variant FTD, the Gorno-Tempini criteria for the semantic variant FTD or non-fluent aphasia, the Movement Disorder Society Task Force criteria for PDD, the vascular behavioral and cognitive disorders (Vas-Cog) criteria for VaD, the Armstrong's criteria for CBD, the CDC's diagnostic criteria for CJD, etc. In addition, normal cognition is supported by MMSE, CDR and other cognitive function scales.\n\nExclusion Criteria:\n\n* Other medical or psychiatric illness. No one can serve as an informant. Refused to complete a cognitive test and provide biospecimen.",true,"ALL","55 Years","75 Years",{"count":72,"type":73},3200,"ESTIMATED","OBSERVATIONAL","The participant in this study includes Alzheimer's disease (AD including familial AD and sporadic AD) patients, amnestic mild cognitive impairment (aMCI) patients, non-AD dementia patients and cognitively normal control.\n\nThe purpose of this study is to establish the best cut-off value of cerebrospinal fluid (CSF) and blood β-amyloid (Aβ) 42\u002F40, total tau (t-tau) , phosphorylated tau ,inflammatory factors, etc. in diagnosis of Alzheimer's disease (AD).",[77],"Alzheimer's Disease",[9],"2026-03-19",{"date":81,"type":82},"2026-03-23","ACTUAL",{"date":84,"type":82},"2018-09-01",{"date":86,"type":73},"2027-09-01",{"name":5,"class":6},1]